{"id":"pf-07852352-influenza-sarna-1","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Monitor","effect":"Decreased atazanavir levels"},{"drug":"Darunavir","action":"Monitor","effect":"Decreased darunavir levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Decreased lopinavir levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Decreased ritonavir levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Decreased saquinavir levels"}],"commonSideEffects":[],"contraindications":["No contraindications mentioned in the provided text."],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"Not mentioned","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07852352-influenza-sarna-1","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:35:59.306467+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:36:18.932972+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:05.636992+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:35:59.374307+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07852352-influenza-sarna-1","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:05.997837+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:07.101401+00:00"}},"allNames":"pf-07852352 influenza sarna 1","offLabel":[],"timeline":[],"aiSummary":"PF-07852352 Influenza saRNA 1, marketed by Pfizer, is an influenza vaccine with a key composition patent expiring in 2028. Its primary competitive advantage lies in its established market presence, though the specific mechanism of action remains undisclosed. The main threat to PF-07852352 Influenza saRNA 1 comes from competing mRNA and taRNA vaccine candidates, as well as vaccines for other viral diseases like SARS-CoV-2 and Zika, which may divert market attention and resources.","brandName":"PF-07852352 Influenza saRNA 1","ecosystem":[],"isGeneric":true,"mechanism":{"target":"influenza virus","novelty":"first-in-class","modality":"RNA-based","drugClass":"antisense oligonucleotide","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of PF-07852352 Influenza saRNA 1 involves the use of a saRNA to target the influenza virus. However, the specific details of this mechanism are not provided. Further research is needed to fully understand how this drug works."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07852352-influenza-sarna-1","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07852352-influenza-sarna-1","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:36:18.933058+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"mRNA vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for influenza vaccines"},{"name":"taRNA vaccine candidate","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for influenza vaccines"},{"name":"SARS-CoV-2 vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for COVID-19 vaccines"},{"name":"COVID-19 vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for COVID-19 vaccines"},{"name":"Zika virus vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for Zika virus vaccines"},{"name":"Ebola virus vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for Ebola virus vaccines"},{"name":"VEEV vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for VEEV vaccines"},{"name":"HIV-1 vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for HIV-1 vaccines"},{"name":"Rabies virus vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for Rabies virus vaccines"},{"name":"Respiratory syncytial virus vaccine","company":"N/A","advantage":"Competes with PF-07852352 Influenza saRNA 1 in the market for Respiratory syncytial virus vaccines"}],"genericName":"pf-07852352-influenza-sarna-1","indications":{"approved":[{"name":"Influenza","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440}],"_emaApprovals":[{"date":"","name":"PF-07852352 Influenza saRNA 1","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"RNA-based","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:36:18.933058+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}